Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients

Frontiers in Oncology

Oncology

Valentina Zampiga¹  Ilaria Cangini¹  Giorgia Gurioli¹  Gianluca Tedaldi¹  Elisabetta Petracci²  Marco Stefanetti³  Andrea Amadori⁴  Alberto Farolfi⁵  Ugo De Giorgi⁵  Maria Concetta Cursano⁵  Cristian Lolli⁵  Giuseppe Schepisi⁵  Salvatore Luca Burgio⁵  Marta Rosati⁶  Claudia Casanova⁷  Valentina Arcangeli⁸ 

[1] Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy;Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy;Department of Gynaecology and Obstetrics, Infermi Hospital, Rimini, Italy;Department of Gynaecology and Obstetrics, Morgagni-Pierantoni Hospital, Forlì, Italy;Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy;Department of Medical Oncology, Infermi Hospital, Rimini, Italy;Oncology Department, Santa Maria delle Croci Hospital, Ravenna, Italy;Romagna Cancer Registry, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy;

关键词: BRCA1/2 mutation;    interval debulking surgery;    ovarian cancer prognosis;    primary debulking surgery;    residual disease;    time to initiation of chemotherapy;   

DOI  :  10.3389/fonc.2023.1221096

 received in 2023-05-11, accepted in 2023-07-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionPrimary debulking surgery (PDS), interval debulking surgery (IDS), and platinum-based chemotherapy are the current standard treatments for advanced ovarian cancer (OC). The time to initiation of adjuvant chemotherapy (TTC) could influence patient outcomes.MethodsWe conducted a multicenter retrospective cohort study of advanced (International Federation of Gynecology and Obstetrics (FIGO) stage III or IV) OC treated between 2014 and 2018 to assess progression-free survival (PFS) and overall survival (OS) in relation to TTC. All patients underwent a germline multigene panel for BRCA1/2 evaluation.ResultsAmong the 83 patients who underwent PDS, a TTC ≥ 60 days was associated with a shorter PFS (hazard ratio (HR) 2.02, 95% confidence interval (CI) 1.04–3.93, p = 0.038), although this association lost statistical significance when adjusting for residual disease (HR 1.52, 95% CI 0.75–3.06, p = 0.244, for TTC and HR 2.73, 95% CI 1.50–4.96, p = 0.001, for residual disease). Among 52 IDS patients, we found no evidence of an association between TTC and clinical outcomes. Ascites, type of chemotherapy, or germline BRCA1/2 mutational status did not influence TTC and were not associated with clinical outcomes in PDS or IDS patients.DiscussionIn conclusion, longer TTC seems to negatively affect prognosis in patients undergoing PDS, especially those with residual disease.

【 授权许可】

Unknown   
Copyright © 2023 Farolfi, Petracci, Gurioli, Tedaldi, Casanova, Arcangeli, Amadori, Rosati, Stefanetti, Burgio, Cursano, Lolli, Zampiga, Cangini, Schepisi and Giorgi